Breaking News

Verdiva Bio Launches as Clinical-Stage Cardiometabolic Company

With over $410 million in financing; to advance portfolio of next-gen oral and injectable treatments with first- or best-in-class potential.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Verdiva Bio Ltd. has launched as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. The company is advancing a portfolio of next-generation oral and injectable treatments with first-in-class or best-in-class potential. Verdiva launches with an Series A financing of $411million, co-led by Forbion and General Atlantic, with additional participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Vent...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics